Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Oncolys BioPharma Inc.
  6. Company
    4588   JP3202170001

ONCOLYS BIOPHARMA INC.

(4588)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.

Number of employees : 32 people.
Sales per Business
20192020Delta
Pharmaceutical1 292.3699.1%313.5799.8% -75.74%
Diagnostics11.480.9%0.610.2% -94.69%
JPY in Million
Sales per region
20192020Delta
Japan1 175.7590.2%138.9144.2% -88.19%
Other Asia123.619.5%90.8328.9% -26.52%
United States4.480.3%84.4426.9% +1784.4%
JPY in Million
Managers
Name Title Age Since
Yasuo Urata President, Representative Director, Head-R&D 65 2004
Kohei Hata Executive Officer, Head-Finance & IR - 2019
Junya Inoue Director & Head-Operations Management - 2021
Fumio Urano Independent Outside Director 78 2013
Keiji Yoshimura Director & Head-Accounting 66 2021
Katsufusa Tachiya Auditor 71 2017
Members of the board
Name Title Age Since
Yasuo Urata President, Representative Director, Head-R&D 65 2004
Yasunari Kashihara Director & Head-Overseas Public Relations 55 2021
Keiji Yoshimura Director & Head-Accounting 66 2021
Fumio Urano Independent Outside Director 78 2013
Junya Inoue Director & Head-Operations Management - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0.01 17,405,200 14,612,338 84.0% 34,962 0.2% 84.0%
Shareholders
NameEquities%
Astellas Pharma Inc. 727,200 4.19%
Yoshihisa Fujioka 578,300 3.33%
Yasuo Urata 543,900 3.14%
Chugai Pharmaceutical Co., Ltd. 456,600 2.63%
Oncolys Biopharma Restricted Stock Compensation Plan 380,300 2.19%
Hitoshi Nakanishi 173,000 1.00%
Yasunari Kashihara 140,000 0.81%
Hitoshi Imamura 138,900 0.80%
Asahi Intecc Co., Ltd. 118,600 0.68%
Keiji Yoshimura 35,500 0.20%
Holdings
NameEquities%Valuation
ONCOLYS BIOPHARMA INC. (4588) 34,962 0.20% 354,085 USD
Company contact information
Oncolys BioPharma, Inc.
Toranomon Towers Office
4-1-28 Toranomon
Minato-Ku
Tokyo 105-0001

Phone : +81.3.5472.1578
Fax : +81.3.5472.1488
Web : http://www.oncolys.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Oncolys BioPharma Inc.